We are live on ! Find out more
CYTO

Altamira Therapeutics Ltd
CYTO

Delisted

CYTO was delisted on the 19th of December, 2024.

Back to rankings

4 hedge funds and large institutions have $31K invested in Altamira Therapeutics Ltd in 2020 Q3 according to their latest regulatory filings, with 4 funds opening new positions, increasing their positions, 0 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 4 → 4 (0)

0% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 4

73% less capital invested

Capital invested by funds: $113K → $31K (-$82K)

Holders
4
Holders Change
–
Holders Change %
0%
% of All Funds
0.08%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
–
Reduced
–
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
HF
HRT Financial
New York
+$22.6K
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$11.7K
3
Osaic Holdings
Osaic Holdings
Arizona
+$2.26K
4
TRCT
Tower Research Capital (TRC)
New York
+$376

Top Sellers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
-$54K
2
WS
Wedbush Securities
California
-$49K
3
Morgan Stanley
Morgan Stanley
New York
-$9.03K
4
UBS Group
UBS Group
Switzerland
-$1.13K
Name Holding Trade Value Shares
Change 		Change in
Stake
HF
1
HRT Financial
New York
$19K +$22.6K +60 New
Susquehanna International Group
2
Susquehanna International Group
Pennsylvania
$10K +$11.7K +31 New
Osaic Holdings
3
Osaic Holdings
Arizona
$2K +$2.26K +6 New
Renaissance Technologies
4
Renaissance Technologies
New York
– -$54K -143 Closed
WS
5
Wedbush Securities
California
– -$49K -131 Closed
Morgan Stanley
6
Morgan Stanley
New York
– -$9.03K -24 Closed
UBS Group
7
UBS Group
Switzerland
– -$1.13K -3 Closed
TRCT
8
Tower Research Capital (TRC)
New York
– +$376 +1 New

CYTO Hedge Fund Activity: Q3 2020 in Review

4 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Altamira Therapeutics Ltd (CYTO) for Q3 2020, worth a combined $31K — down 73% from $113K a quarter earlier.

Fund positioning in CYTO was balanced in Q3 2020: 4 funds opened new positions, 4 closed out, 0 added to existing stakes and 0 trimmed.

The largest buyer was HRT Financial, opening a new position worth an estimated $22.6K. The largest seller was Renaissance Technologies, exiting entirely with an estimated $54K sold.

  • 4 institutional investors held Altamira Therapeutics Ltd (CYTO) as of Q3 2020, unchanged from Q2 2020.
  • Funds reported $31K of Altamira Therapeutics Ltd stock for Q3 2020, down 73% quarter-over-quarter.
  • 4 funds opened new Altamira Therapeutics Ltd positions in Q3 2020 and 4 closed out, a net change of 0 holders.
  • The largest Altamira Therapeutics Ltd buyer in Q3 2020 was HRT Financial, an estimated $22.6K added.
  • The largest Altamira Therapeutics Ltd seller in Q3 2020 was Renaissance Technologies, an estimated $54K sold.

Based on aggregated 13F filings for Q3 2020.